---
layout: default
title: Toremifene
parent: AI Predictions (L5)
nav_order: 630
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-15
description: "Toremifene: predicted new indication HIV infectious disease (evidence level L5). Approved use: First line hormone treatment of hormone-dependent metastatic breast c…"
---

# Toremifene
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Toremifene: From Hormone-Dependent Metastatic Breast Cancer to HIV Infectious Disease

## One-Sentence Summary

Toremifene was originally approved in the EU as first-line hormone treatment for hormone-dependent metastatic breast cancer in postmenopausal patients.
The TxGNN model predicts it may be effective for **HIV infectious disease**, but there are **0 clinical trials** and only **1 preclinical publication** (on an antifungal effect, not on HIV itself) supporting this direction.
The prediction is therefore a computational signal with no clinical backing.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours. |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L5 (model prediction only; no actual studies on HIV) |
| EU Market Status | ✗ Cancelled only |
| Number of Authorizations | 1 (0 currently valid, 1 cancelled) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, toremifene is a selective estrogen receptor modulator (SERM) related to tamoxifen. Its efficacy in hormone-dependent breast cancer is established, but no direct mechanism links it to HIV.

The only linked paper (PMID 24520056) shows that estrogen receptor antagonists, including toremifene, have antifungal activity against *Cryptococcus*. They act by binding EF-hand proteins such as calmodulin and work together with fluconazole in the laboratory. This is relevant to an opportunistic fungal infection that affects people with HIV, not to HIV replication or disease progression. The high score is most likely driven by similarity patterns in the knowledge graph rather than by biological evidence.

Other predictions for this drug include AIDS, feline AIDS and simian immunodeficiency virus infection, which cluster around the same HIV-related signal. Breast carcinoma also appears among the predictions, but that is toremifene's existing indication rather than a new one.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [24520056](https://pubmed.ncbi.nlm.nih.gov/24520056/) | 2014 | Preclinical (in vitro/in vivo antifungal study) | mBio | Tamoxifen and toremifene are fungicidal against *Cryptococcus* and synergize with fluconazole and amphotericin B. Activity is linked to binding of EF-hand proteins. This does not show an effect on HIV. |

---

## EU Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| EMEA/H/C/000091 (cancelled) | Fareston | Not specified | First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for pa... |

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Hormonal (endocrine) therapy, SERM class. It is not a conventional cytotoxic agent. |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions. Leukopenia and thrombocytopenia appear among the knowledge-graph contraindication links. |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions. Given the QT-related concerns below, ECG and electrolyte monitoring are reasonable considerations. |
| Handling Protection | Please refer to the SmPC warnings and precautions |

---

## Safety Considerations

- **Contraindication signals from the knowledge graph (not label text):** long QT syndrome, familial long QT syndrome, torsades de pointes, thrombocytopenia, potassium deficiency disease, hypercalcemia, nephrocalcinosis, phosphorus metabolism disease, leukopenia, endometrial hyperplasia.
- **Drug interactions:** 100 interactions are recorded. The 20 reviewed include these **Major** interactions: dexamethasone, clarithromycin, picosulfuric acid, polyethylene glycol (3350 with electrolytes), dolasetron, palonosetron, sodium sulfate and levofloxacin. Many of these are QT-prolonging or electrolyte-altering drugs. Moderate interactions include famotidine, cimetidine, pioglitazone, loperamide, aprepitant, bisacodyl, miconazole, nateglinide, lactitol and lactulose.

Please refer to the SmPC for the full label warnings and contraindications.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV prediction has a very high model score but no clinical trials and no evidence of anti-HIV activity. The single linked paper concerns an antifungal effect. The EU authorization is cancelled, and the QT-related and interaction risks are significant in a population that often takes many medicines.

**To proceed, the following is needed:**
- Laboratory evidence that toremifene directly inhibits HIV replication, or a defined mechanism linking it to HIV disease
- Mechanism of action (MOA) data
- Safety, QT-risk and interaction assessment for people with HIV on antiretroviral therapy
- Review of the SmPC warnings and contraindications, which are not yet available
- Clarification of current availability, since the only EU authorization is cancelled
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

